Oncology biomarker testing is now used for applications including treatment selection, prognosis, and monitoring drug response / tumor progression. We forecast that the cancer biomarker testing market size will grow at ~11% p.a. from ~$2.7B in 2017 to ~$3.7B in 2020.
